Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer
Executive Summary
FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains
You may also be interested in...
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics